TB-500 – 10 mg

TB-500 is commonly described as a synthetic peptide fragment corresponding to the LKKTETQ sequence associated with the central actin-binding region of thymosin beta-4. This region has been investigated in laboratory research involving actin dynamics, cellular migration, and signaling pathways associated with angiogenesis and tissue-response mechanisms. The 10 mg presentation is intended for qualified research environments conducting controlled investigations into peptide pharmacology, actin-associated mechanisms, cellular signaling, cell migration, and related preclinical models.

Key Features

10 mg research-grade TB-500 TB-500 / thymosin beta-4 fragment LKKTETQ peptide sequence Relevant to actin-associated research Suitable for cellular signaling and peptide pharmacology studies Intended for controlled in-vitro and preclinical research Appropriate for peptide characterization and analytical workflows Batch-level analytical documentation may be provided for applicable lots Research Focus Research into thymosin beta-4 and related peptide fragments has examined actin binding, cell migration, angiogenic processes, and cellular responses. The LKKTETQ region has been identified as an actin-binding domain within thymosin beta-4, providing a basis for investigating its molecular interactions and associated cellular pathways. TB-500 remains a research compound with limited human safety data. FDA has specifically noted concerns regarding immunogenicity, aggregation, peptide-related impurities, and insufficient human exposure information for TB-500-related substances.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. TB-500 should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols, analytical requirements, and regulations.